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Abstract. The brain is one of the most common sites for the 
metastasis of small cell lung cancer (SCLC). The present study 
describes two cases of an isolated solitary brain metastasis as a 
relapse of SCLC, which occurred more than one year after the 
completion of the initial successful treatment for SCLC. The 
tumors were identified during a regular check‑up computed 
tomography (CT) scan and were successfully treated. To the 
best of our knowledge, this is the first study to report the cases 
of two patients with an isolated solitary brain metastasis as a 
relapse of SCLC. Although extremely rare, the possibility of 
such recurrences should be considered, particularly in patients 
who have refused prophylactic cranial irradiation.
Introduction
Despite good responses to chemotherapy and chemoradio-
therapy, small cell lung cancer (SCLC) is characterized by 
early and widespread metastases (1). Brain metastases are 
observed in ~10% of patients at the time of the initial diag-
nosis, and an additional 40-50% may develop brain metastases 
during the course of their disease (1). However, late isolated 
solitary brain metastasis as a relapse of SCLC is rare (2). The 
present study describes two SCLC patients with an isolated 
solitary brain metastasis at 18 and 14 months, respectively, 
following the completion of an initial successful treatment for 
SCLC. This case report conformed to the Ethical Guidelines 
for Clinical Studies issued by the Ministry of Health, Labor 
and Welfare of Japan. Comprehensive informed consent with 
regard to clinical significance was obtained from the patients.
Case reports
Case 1. A 63-year-old male was admitted to the University of 
Tsukuba Hospital (Mito, Japan) for an examination of a chest 
nodule in the right upper lobe of the lung. On admission, the 
laboratory examination revealed a hemoglobin level of 13.9 g/
dl, a hematocrit level of 41.6% and a lactate dehydrogenase 
level of 139 IU/l. The serum level of neuron‑specific enolase 
(NSE) was 19.9 ng/ml and the pro-gastrin-releasing peptide 
(proGRP) level was elevated to 522.1 pg/ml. A chest X-ray and 
computed tomography (CT) scan revealed a poorly‑defined 
mass in the upper lobe of the right lung, with an ipsilateral 
mediastinal lymph node swelling. A transbronchial biopsy 
revealed the tumor to be SCLC. As no metastatic lesion was 
identified, the tumor was diagnosed as limited disease‑SCLC. 
The patient was treated using chemoradiotherapy (chest 
irradiation up to 65 Gy and four courses of chemotherapy) 
containing cisplatin (80 mg/m2, day 1 for 4 weeks) and 
etoposide (100 mg/m2, days 1‑3, for 4 weeks), which resulted 
in a complete response (CR). A requirement for prophylactic 
cranial irradiation (PCI) was indicated, however, whole brain 
irradiation was not administered as the patient did not want the 
therapy. Subsequent to 18 months from the initial diagnosis of 
SCLC, a metastatic lesion was observed in the right temporal 
lobe of the cerebral hemisphere during a follow-up magnetic 
resonance imaging (MRI) scan (Fig. 1). The patient was 
administered 30 Gy whole grain irradiation and four courses 
of platinum-containing chemotherapy consisting of cisplatin 
(80 mg/m2, day 1 for 4 weeks) and etoposide (100 mg/m2, 
days 1‑3 for 4 weeks). The patient eventually succumbed to 
cardiac disease seven years after the recurrence. However, no 
further recurrence was observed until the patient succumbed. 
Case 2. A 67-year-old male was admitted to Mito Medical 
Center, University of Tsukuba (Mito, Japan) for an examina-
tion of a chest nodule in the right upper lobe of the lung. On 
admission, the laboratory examination revealed a hemoglobin 
level of 15.0 g/dl, a hematocrit level of 42.7% and a lactate 
dehydrogenase level of 223 IU/l. The serum level of NSE was 
9.2 ng/ml and the proGRP level was 12.7 pg/ml. A chest X-ray 
and CT scan revealed a poorly‑defined mass in the upper lobe 
of the right lung, with an ipsilateral mediastinal lymph node 
swelling. A transbronchial biopsy revealed the tumor to be 
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SCLC. As no metastatic lesion was identified, the tumor was 
diagnosed as a limited disease-SCLC. The patient was treated 
using chemoradiotherapy (chest irradiation up to 65 Gy and 
four courses of chemotherapy) containing cisplatin (80 mg/m2, 
day 1 for 4 weeks) and etoposide (100 mg/m2, days 1-3 for 
4 weeks), which resulted in a CR. A requirement for prophy-
lactic cranial irradiation (PCI) was indicated, however, it was 
not administered to the patient as he was concerned about a 
decline in intellectual level due to the possible neuropsycho-
logical problems associated with the treatment. At 14 months 
after the initial diagnosis of SCLC, a metastatic lesion was 
identified in the left cerebellar hemisphere on a follow‑up MRI 
scan (Fig. 2). The patient was administered 30 Gy whole grain 
irradiation and four courses of platinum-containing chemo-
therapy. The patient remains well at 30 months post-recurrence.
Discussion
The late relapse of lung cancer has been a growing topic of 
discussion due to the high level of curability and the possi-
bility of a long survival time in patients. Among the various 
malignancies, the late relapse of SCLC is well known but 
uncommon (2-5). In the literature, there have been seven 
cases of SCLC that have relapsed following ≥10 years of 
disease-free survival (6-11). In all the cases, the relapse 
occurred in the intrathoracic region, including in the lungs, 
the mediastinal lymph nodes or the pleural space. Three 
cases also experienced brain metastasis (6,8,10). Patients 
with lung adenocarcinomas rarely develop isolated soli-
tary brain metastasis and certain patients have favorable 
prognoses (3-5). The present study describes two cases of 
an isolated solitary brain metastasis as a relapse of SCLC. 
The literature was searched for the cases of patients with a 
late isolated solitary brain metastasis as a relapse of SCLC, 
and only one such case was identified (2). The patient was a 
long-term survivor of SCLC who was treated with radiation 
alone and suffered a rare relapse of SCLC, with a solitary 
brain metastasis 6.5 years after the initial treatment (2). The 
patient was administered radiation therapy and succumbed to 
the brain metastasis 8.5 years after the initial treatment (2). 
An autopsy revealed no tumor recurrence at the primary site 
and no distant metastases, with the exception of the brain 
metastasis. The histology of the brain tumor was confirmed 
to be that of SCLC (2). In the patients of the present study, the 
brain metastases were identified during a routine follow‑up 
brain CT scan or MRI, without any presenting symptoms. 
The patients were disease free for more than two years after 
the successful treatment using whole brain irradiation and 
additional platinum-containing chemotherapy. A pathological 
confirmation of the brain metastasis was not obtained. No 
other disease was located using systemic imaging evaluation 
at the time of the identification of the brain lesion and there 
was a good response to the whole brain irradiation and subse-
quent chemotherapy. The tumors were evaluated clinically as 
brain metastases from SCLC. With the exception of patients 
with tumors of the lung, there have only been two patients 
Figure 1. (A and B) Case 1: A metastatic lesion was identified in the right tem-
poral lobe of the cerebral hemisphere during a follow-up magnetic resonance 
imaging (MRI) examination. (A) Transverse section; (B) coronal section.
Figure 2. (A and B) Case 2: A metastatic lesion was identified in the left cer-
ebellar hemisphere during a follow-up magnetic resonance imaging (MRI) 
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with isolated brain metastasis as the sole manifestation of a 
late relapse (12,13). One case was of a late onset of isolated 
intracranial metastasis of a liposarcoma in the right lower 
extremity (12). The relapse was identified 26 years after the 
initial therapy (12). The other case was of an isolated brain 
metastasis in a patient with breast cancer nine years after the 
initial therapy (13). In the two cases, additional therapy was 
unsuccessful in controlling the disease progression (12,13). 
The mechanism of this form of rare metastasis remains to 
be elucidated. SCLC cells metastasize at a certain point of 
their clinical course and may survive at the metastatic sites, 
escaping from the immune mechanism with no rapid growth. 
Following a period of long-term dormancy, the cells may then 
initiate growth again (14).
PCI has been proposed as a form of treatment in SCLC 
that reduces the incidence of brain metastases and significantly 
improves overall survival in limited- and extensive disease-SCLC 
in patients who respond to first‑line treatment (15). It has been 
suggested that this treatment may increase neuropsycho-
logical syndromes and brain abnormalities, as indicated by CT 
scans (16,17). However, no significant increase in late sequelae 
has been shown in clinical trials between patients with and 
without PCI (14,18,19). As the patients in the present study had 
the limited disease form, they were informed that there were 
indications that PCI should be performed at the time of their 
good response to first‑time treatment. The patients refused PCI 
for fear of the appearance of neuropsychological symptoms. 
However, once diagnosed with an isolated solitary brain metas-
tasis, the patients underwent whole brain irradiation. The two 
patients developed no neuropsychological symptoms. 
To the best of our knowledge, the two cases of isolated soli-
tary brain metastasis relapse of SCLC of the present study are 
the first to have been described. As shown in the present study, 
there are patients who may be expected to have long-term 
survival following the additional therapy for brain metastasis, 
therefore careful follow-up is necessary to detect metastatic 
lesions as early as possible, particularly for patients who have 
refused PCI.
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